At the Society of Urologic Oncology Annual Meeting, Arvin George, MD, Johns Hopkins, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, discuss a new trial using a treatment modality for prostate tissue ablation in intermediaterisk prostate cancer, counseling patients on the notion of focal therapy, and considerations for posttreatment surveillance.